Nanjing Nuovezan Biotechnology Co., Ltd. non-operating capital occupation and

Other related capital transactions

2024 year

About Nanjing Nuovezan Biotechnology Co., Ltd

Occupation of non-operating funds and other related capital transactions

Special reports

Xinhuishi Bao Zi [2025] No. ZA10733

All shareholders of Nanjing Nuovezan Biotechnology Co., Ltd.:

We conducted an audit of Nanjing Nuovezan Biotechnology Co., Ltd. (hereinafter referred to as "Novizan

Like") financial statements for the year 2024, including consolidated and parent company for the year ended December 31, 2024

Balance Sheet, 2024 Consolidated and Parent Income Statement, Consolidated and Parent Cash Flow Statement, Consolidated and Parent Statement of Changes in Owners' Equity and Notes to Related Financial Statements, and

On April 8, 2025, the report number was issued as Xinhuishi Bao Zi [2025] No. ZA10730

of the unqualified audit report.

In accordance with the relevant provisions of the Regulatory Guidelines for Listed Companies No. 8 of the China Securities Regulatory Commission - Regulatory Requirements for Capital Transactions and External Guarantees of Listed Companies (CSRC Announcement [2022] No. 26) and the Shanghai Stock Exchange's Self-Regulatory Guidelines for Listed Companies on the Science and Technology Innovation Board No. 7 - Matters Related to Annual Reports, the management of Novozan has prepared the attached summary table of the occupation of non-operating funds and other related capital transactions in 2024 (hereinafter referred to as the "Summary Table").

It is the responsibility of the management of Novozan to compile the summary and ensure that it is true, accurate and complete. We have reconciled the information contained in the summary statements with the accounting information we audited in our audit of the 2024 financial statements and the disclosures in the audited financial statements and found no material inconsistencies.

In order to better understand the 2024 non-operating capital occupation and other related capital transactions of Novozan, the summary statement should be read together with the audited financial statements.

This report is for the sole purpose of disclosing the 2024 Annual Report and not for any other purpose.

Lixin Certified Public Accountants Chinese Certified Public Accountants:

(Special General Partnership)

Chinese Certified Public Accountants:

Shanghai, China April 8, 2025